NCT03744403 is a Phase 1 clinical trial of CS1001 in Advanced Solid Tumors, sponsored by CStone Pharmaceuticals.

Who is sponsoring NCT03744403?

NCT03744403 is sponsored by CStone Pharmaceuticals.

What drugs are being tested in NCT03744403?

Interventions in NCT03744403: CS1001.

What condition does NCT03744403 study?

NCT03744403 studies Advanced Solid Tumors.

Is NCT03744403 still recruiting?

NCT03744403 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT03744403

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CS1001 in Subjects with Advanced Solid Tumors

Completed Phase 1 Last updated 19 September 2024

What this trial tests

Phase 1 trial testing CS1001 in Advanced Solid Tumors in 24 participants. Completed in 21 July 2021.

Timeline

4 December 2018

Primary endpoint
31 October 2020

21 July 2021

Quick facts

Lead sponsor	CStone Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	4 December 2018
Primary completion	31 October 2020
Estimated completion	21 July 2021
Sites	1 location across United States

Drugs / interventions tested

CS1001

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

CStone Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.
Yang H, Wang K, Wang T, Li M, et al · · 2020 · cited 35× · PMID 32195194 · DOI 10.3389/fonc.2020.00300
Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review.
Xie T, Feng Q, Li Z, Lu M, et al · · 2021 · cited 10× · PMID 33422121 · DOI 10.1186/s13053-021-00165-2

Verify or expand the search:

Other trials of CS1001

Trials testing the same drug.

NCT04421352 — Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients · Phase 1 · completed
NCT04200404 — A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors · Phase 1, PHASE2 · completed
NCT03595657 — A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) · Phase 2 · completed
NCT03505996 — A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma · Phase 2 · completed
NCT03312842 — A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors · Phase 1 · completed

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other CStone Pharmaceuticals trials

Trials by the same sponsor.

NCT05381753 — Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World · completed
NCT05279300 — A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas · Phase 1 · recruiting
NCT04421352 — Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients · Phase 1 · completed
NCT04233060 — A Study of CS3005 in Advanced Solid Tumors · Phase 1 · completed
NCT04162301 — A Study of CS3002 in Subjects With Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03744403 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CStone Pharmaceuticals
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03744403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing